Bristol Warns Physicians Of Early Virologic Failure With Videx EC Regimens
This article was originally published in The Pink Sheet Daily
Executive Summary
"Dear Doctor" letter recommends "caution" when co-administering Videx EC, Gilead's Viread and Bristol's Sustiva or BI's Viramune in treatment-naïve HIV patients with high viral loads. The virologic data could eventually be included in labeling, Bristol says.
You may also be interested in...
Barr’s Videx EC Generic Carries 180-Day Marketing Exclusivity
FDA approved the first ANDA for Bristol’s antiretroviral after completing expedited review under the President’s Emergency Plan for AIDS Relief, Barr says. Expiration of a data exclusivity agreement between Bristol and NIH in May 2004 cleared the way for Barr’s ANDA filing.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter